First Bank & Trust Invests $248,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

First Bank & Trust purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,031 shares of the company’s stock, valued at approximately $248,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Hennion & Walsh Asset Management Inc. grew its holdings in shares of BridgeBio Pharma by 18.4% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 144,094 shares of the company’s stock worth $4,455,000 after purchasing an additional 22,441 shares during the last quarter. Nomura Holdings Inc. boosted its holdings in BridgeBio Pharma by 9.8% in the fourth quarter. Nomura Holdings Inc. now owns 257,995 shares of the company’s stock valued at $10,415,000 after acquiring an additional 22,986 shares during the last quarter. Vanguard Group Inc. boosted its holdings in BridgeBio Pharma by 13.5% in the fourth quarter. Vanguard Group Inc. now owns 12,800,294 shares of the company’s stock valued at $516,748,000 after acquiring an additional 1,524,313 shares during the last quarter. Wellington Management Group LLP boosted its holdings in BridgeBio Pharma by 5.3% in the fourth quarter. Wellington Management Group LLP now owns 1,495,114 shares of the company’s stock valued at $60,358,000 after acquiring an additional 75,564 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in BridgeBio Pharma in the fourth quarter valued at approximately $245,000. 99.85% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the company. UBS Group reduced their target price on BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating on the stock in a report on Tuesday, May 28th. Raymond James assumed coverage on BridgeBio Pharma in a report on Thursday, March 21st. They issued an “outperform” rating and a $45.00 target price on the stock. Mizuho reduced their target price on BridgeBio Pharma from $60.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday, March 5th. Bank of America reduced their target price on BridgeBio Pharma from $50.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, June 25th. Finally, HC Wainwright restated a “buy” rating and set a $43.00 price target on shares of BridgeBio Pharma in a report on Thursday, June 20th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $47.21.

Insider Transactions at BridgeBio Pharma

In related news, Director Randal W. Scott sold 1,000 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $28.84, for a total value of $28,840.00. Following the completion of the sale, the director now directly owns 5,500 shares of the company’s stock, valued at approximately $158,620. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 24.66% of the stock is owned by insiders.

BridgeBio Pharma Stock Up 0.5 %

Shares of NASDAQ:BBIO opened at $25.33 on Friday. BridgeBio Pharma, Inc. has a twelve month low of $16.61 and a twelve month high of $44.32. The stock’s 50 day moving average is $27.38 and its 200-day moving average is $31.58.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Thursday, May 2nd. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.35. The firm had revenue of $211.12 million for the quarter, compared to analyst estimates of $140.06 million. Equities analysts anticipate that BridgeBio Pharma, Inc. will post -3.2 EPS for the current fiscal year.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.